Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SGMS2 | Q8NHU3 | 6/20 | 0.59 |
| ▸ | NPC1 | O15118 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 4/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | PPIA | P62937 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | FAAH | O00519 | 1/20 | 0.50 |
| ▸ | CNR1 | P21554 | 1/20 | 0.50 |
| ▸ | CNR2 | P34972 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4148770 | 1.00 | SGMS2 (0.59) | SGMS2NPC1MEN1KMT2AGAA | |
| SCHEMBL4148774 | 1.00 | SGMS2 (0.59) | SGMS2NPC1MEN1KMT2AGAA | |
| SCHEMBL13851702 | 0.90 | TSHR (0.59) | SGMS2NPC1MEN1KMT2AGAA | |
| SCHEMBL4147984 | 0.85 | SGMS2 (0.67) | SGMS2NPC1MEN1KMT2AGAA | |
| SCHEMBL4147978 | 0.85 | SGMS2 (0.67) | SGMS2NPC1MEN1KMT2AGAA | |
| SCHEMBL5438643 | 0.82 | CTSD (0.55) | NPC1MEN1KMT2AGAALMNA | |
| SCHEMBL5438647 | 0.82 | CTSD (0.55) | NPC1MEN1KMT2AGAALMNA | |
| SCHEMBL5438640 | 0.82 | CTSD (0.55) | NPC1MEN1KMT2AGAALMNA | |
| SCHEMBL14428116 | 0.79 | SGMS2 (0.75) | SGMS2NPC1MEN1KMT2AGAA | |
| SCHEMBL974381 | 0.77 | SGMS2 (0.72) | SGMS2NPC1MEN1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137557-A1 | Calcilytic Compounds | SMITHKLINE BEECHAM CORPORATION | 2009-05-28 | — | — | US | disclosed |
| EP-1951244-A2 | CALCILYTIC COMPOUNDS | SmithKline Beecham Corporation (US) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007062370-A2 | CALCILYTIC COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137557-A1 | Calcilytic Compounds | CALCR, SOST, CALCB | SGMS2 266/4885NPC1 503/4885MEN1 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.